TIDMSENS

RNS Number : 5022T

Sensyne Health PLC

15 November 2019

Sensyne Health names Cognizant and Agorai as partners for the launch and sale of its digital health software products in the U.S.

Financial returns from US to be shared with the UK NHS

via Sensyne's unique partnership model

Oxford, UK; 15 November 2019: Sensyne Health plc (LSE: SENS), ("Sensyne Health" or "the Company"), the British clinical AI technology company, today announces the name of its partners for the launch and sale of its digital health software products in the United States of America. Further to the announcement made on 7 October 2019 regarding the signed agreements with a Fortune 200 company and a data infrastructure specialist, Sensyne Health is now pleased to name Cognizant, the American multinational corporation and leading provider of information technology, consulting, and business process services in healthcare, and Agorai, a data infrastructure specialist, as its partners.

The initial Sensyne Health digital health software products that will be exclusively sold in the US under these agreements are GDm-Health (for the management of gestational diabetes), EDGE (for the management of COPD) and Support-HF (for the management of heart failure). GDm-health will be launched first, which is currently in use by 15 NHS Trusts and has helped over 6,100 patients in the UK managing and controlling gestational diabetes, a common condition that can lead to high blood pressure, premature birth or the need for Caesarean section. No UK patient data will be shared under these agreements.

These products were originally invented and developed in the UK's NHS in collaboration with the University of Oxford and then licensed to Sensyne Health. The financial returns made by Sensyne Health under these major agreements with Cognizant and Agorai will be shared with the NHS under Sensyne's unique partnership model.

Lord (Paul) Drayson PhD, CEO of Sensyne Health, said: "Cognizant and Agorai are excellent partners that will enable us to ensure that the full potential of these innovative products, first invented in the UK's NHS, is realised in the US market. Following the appropriate regulatory approvals, Cognizant will provide these digital health applications to US health care providers and the commercial return made by Sensyne will be shared with the NHS."

-ENDS-

For more information please contact:

 
                                                   +44 (0) 330 058 
  Sensyne Health (www.sensynehealth.com)            1845 
  Lord (Paul) Drayson, Chief Executive Officer 
  Lorimer Headley, Chief Financial Officer 
 
  Peel Hunt LLP (Nominated Adviser and Joint       + 44 (0) 20 7418 
   Broker)                                          8900 
  Dr Christopher Golden 
  James Steel 
  Oliver Jackson 
 
                                                   + 44 (0) 20 3100 
  Liberum (Joint Broker)                            2000 
  Bidhi Bhoma 
  Euan Brown 
 
  Consilium Strategic Communications               +44 20 3709 5700 
  Mary-Jane Elliott 
  Sukaina Virji 
  Melissa Gardiner 
  sensynehealth@consilium-comms.com

About Cognizant

Cognizant (Nasdaq-100: CTSH) is one of the world's leading professional services companies, transforming clients' business, operating and technology models for the digital era. Our unique industry-based, consultative approach helps clients envision, build and run more innovative and efficient businesses. Headquartered in the U.S., Cognizant is ranked 193 on the Fortune 500 and is consistently listed among the most admired companies in the world. Learn how Cognizant helps clients lead with digital at www.cognizant.com or follow us @Cognizant.

About Agorai

Agorai helps companies accelerate commercial returns from AI solutions and data assets. The team continuously curates applied AI solutions, connecting them with companies that can best benefit from them, and helping those companies to quickly deliver meaningful, bottom-line value. Learn more at www.agorai.ai

About Sensyne Health

Sensyne Health plc is a clinical AI company that works in partnership with the NHS to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is an early signatory to the U.K Department of Health and Social Care's 'Initial Code of Conduct for data-driven health and care technology. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L). For more information, please visit: www.sensynehealth.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

MSCDDBDBLDBBGCS

(END) Dow Jones Newswires

November 15, 2019 02:00 ET (07:00 GMT)

Grafico Azioni Sensyne Health (LSE:SENS)
Storico
Da Mar 2024 a Apr 2024 Clicca qui per i Grafici di Sensyne Health
Grafico Azioni Sensyne Health (LSE:SENS)
Storico
Da Apr 2023 a Apr 2024 Clicca qui per i Grafici di Sensyne Health